Chinese Academy of Sciences

University of Texas System

Auckland Uniservices Limited

Jinan University

Shanghai Haihe Pharmaceutical Co., Ltd.

Guangzhou Institute of Biomedicine and Health

Sansure Biotech Inc.

Haihe Biopharma Co., Ltd.

Xiaomei Ren

Ke Ding

Zhengchao Tu

Meiyu Geng

Jian Ding

Zhang Zhang

Dongmei Zhang

Yi Chen

Rolf A Brekken

Jeffrey Bruce Smaill

Adam Vorn Patterson

Jing Ai

Swarnalatha Akuratiya Gamage

Xia Peng

Amir Ashoorzadeh

Christopher Paul Guise

Lizhong Dai

Yinchun Ji

Xiaoyun Lu

Hua Xie

Li Tan

Zhen Wang

Yang Dai

Christopher John Squire

Matthew Roy Bull

Donglin Gao

Maria Rosaria Abbattista

Shingpan Chan

Kristina Y Aguilera

Angus Cheverton Grey

Xueqiang Li

Deyong Tan

Shuang Jiang

Wang Wan

Xiaoliang Chen

Jin Yan

Jia Liu

Kang Wu

Qingzhi Sun

Xing Cheng

Xinwu Guo

Bozhi Ji

Zhongping Deng

Fibroblast Growth Factor Receptor kinase inhibitors and prodrugs thereof of Formula (I) and their use for the treatment of hyper-proliferative diseases such as retinopathy, psoriasis, rheumatoid arthritis, osteoarthritis, septic arthritis, tumour metastasis, periodontal disease, corral ulceration, proteinuria, coronary thrombosis from atherosclerotic plaque, aneurismal aorta, dystrophobic epidermolysis bullosa, degenerative cartilage loss following traumatic joint injury, osteopenias mediated by MMP activity, tempero mandibular joint disease, and demyelating disease of the nervous system.

FGFR kinase inhibitors and pharmaceutical uses

Provided are a substituted quinolone derivative as shown by formula (I), or a pharmaceutically acceptable salt and a prodrug molecule thereof, and a pharmaceutical composition thereof, as well as the use of same in preparing drugs for the prevention and treatment of a tumor. The quinolone derivative, salt, prodrug molecule, and pharmaceutical composition thereof can be used as a protein kinase inhibitor, which is effective in inhibiting the activity of AXL protein kinase, and is capable of inhibiting the proliferation, migration and invasion of various tumor cells; and can be used in the preparation of anti-tumor drugs, especially drugs for treating hyperproliferative diseases such as a tumor in human beings and other mammals.

Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof

Compounds of formula (I), their pharmaceutically acceptable salts and stereoisomers thereof, as well as application in effectively inhibiting the enzymatic activity of discoidin domain receptor 1 and can be used as new therapeutic agents for preventing and treating e.g. inflammation, liver fibrosis, kidney fibrosis, lung fibrosis, skin scar, atherosclerosis, and cancer. The compound of formula I is: wherein the variables are as defined herein. 

Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof

Disclosed are a 2-aminopyrimidine compound and pharmaceutical composition and use thereof. The structure of the 2-aminopyrimidine compound is as represented by formula I, in the formula, R, R, R, R, R, X, Y, Z, W, (i) being as defined in the specification and the claims. Such compounds effectively inhibit the growth of a variety of tumor cells and have inhibitory effects on EGFR and IGF1R protease, and can be used for preparing antineoplastic drugs and overcome the tolerance induced by the existing drugs such as gefitinib, erlotinib and the like. The compound has selectivity for tumors, in particular the wild-type non-small cell lung cancer and have good pharmacokinetic characteristics. 

2-aminopyrimidine compound and pharmaceutical composition and use thereof

Growing community of inventors

Guangdong, China

Xiaomei Ren